Sanofi EBITDA Margin 2010-2024 | SNY
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Sanofi (SNY) over the last 10 years. The current EBITDA margin for Sanofi as of September 30, 2024 is .
| Sanofi EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| 2024-09-30 |
$53.03B |
$8.54B |
16.11% |
| 2024-06-30 |
$51.29B |
$7.84B |
15.29% |
| 2024-03-31 |
$50.68B |
$8.45B |
16.67% |
| 2023-12-31 |
$50.27B |
$9.59B |
19.08% |
| 2023-09-30 |
$49.01B |
$10.30B |
21.03% |
| 2023-06-30 |
$48.42B |
$11.11B |
22.95% |
| 2023-03-31 |
$48.20B |
$10.71B |
22.21% |
| 2022-12-31 |
$47.82B |
$10.72B |
22.42% |
| 2022-09-30 |
$48.72B |
$12.21B |
25.07% |
| 2022-06-30 |
$46.20B |
$10.43B |
22.58% |
| 2022-03-31 |
$46.31B |
$11.73B |
25.32% |
| 2021-09-30 |
$45.31B |
$11.37B |
25.10% |
| 2021-03-31 |
$43.57B |
$10.31B |
23.66% |
| 2020-09-30 |
$42.75B |
$9.32B |
21.80% |
| 2020-03-31 |
$41.19B |
$7.94B |
19.28% |
| 2019-09-30 |
$41.49B |
$6.79B |
16.37% |
| 2019-03-31 |
$41.50B |
$6.71B |
16.17% |
| 2018-03-31 |
$41.43B |
$6.77B |
16.33% |
| 2017-12-31 |
$40.92B |
$7.07B |
17.27% |
| 2017-09-30 |
$40.25B |
$7.72B |
19.19% |
| 2017-06-30 |
$39.59B |
$8.01B |
20.24% |
| 2017-03-31 |
$39.14B |
$8.14B |
20.79% |
| 2016-12-31 |
$38.41B |
$7.59B |
19.77% |
| 2016-09-30 |
$39.27B |
$8.06B |
20.52% |
| 2016-06-30 |
$39.37B |
$7.47B |
18.97% |
| 2016-03-31 |
$41.16B |
$7.72B |
18.76% |
| 2015-09-30 |
$42.97B |
$7.96B |
18.53% |
| 2015-06-30 |
$43.92B |
$11.02B |
25.10% |
| 2014-06-30 |
$44.70B |
$11.47B |
25.67% |
| 2013-06-30 |
$45.22B |
$11.54B |
25.53% |
| 2012-06-30 |
$46.75B |
$12.18B |
26.06% |
| 2012-03-31 |
$47.10B |
$8.41B |
17.86% |
| 2011-12-31 |
$47.27B |
$8.89B |
18.80% |
| 2011-09-30 |
$45.65B |
$8.20B |
17.97% |
| 2011-06-30 |
$44.35B |
$8.97B |
20.23% |
| 2011-03-31 |
$42.93B |
$10.32B |
24.03% |
| 2010-12-31 |
$41.26B |
$9.22B |
22.33% |
| 2010-09-30 |
$41.28B |
$8.91B |
21.59% |
| 2010-06-30 |
$41.42B |
$8.83B |
21.33% |
| 2010-03-31 |
$41.35B |
$8.80B |
21.28% |
| 2009-12-31 |
$40.79B |
$8.81B |
21.60% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$120.547B |
$46.611B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
